Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer

J Thorac Oncol. 2014 Mar;9(3):e21-3. doi: 10.1097/JTO.0000000000000013.

Authors

Shengxiang Ren¹, Fred R Hirsch, Marileila Varella-Garcia, Dara L Aisner, Theresa Boyle, Caicun Zhou, D Ross Camidge

Affiliation

¹ *Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, People's Republic of China; †Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado; and ‡Department of Pathology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado.

No abstract available

Publication types

Case Reports

MeSH terms

Adenocarcinoma / genetics*
Adenocarcinoma / metabolism
Adenocarcinoma / secondary
Adult
Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung / genetics*
Carcinoma, Non-Small-Cell Lung / metabolism
Carcinoma, Non-Small-Cell Lung / secondary
Crizotinib
Gene Rearrangement*
Humans
Immunoenzyme Techniques
In Situ Hybridization, Fluorescence
Lung Neoplasms / genetics*
Lung Neoplasms / metabolism
Lung Neoplasms / pathology
Male
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
RNA, Messenger / genetics
Real-Time Polymerase Chain Reaction
Receptor Protein-Tyrosine Kinases / genetics*
Receptor Protein-Tyrosine Kinases / metabolism
Reverse Transcriptase Polymerase Chain Reaction

Substances

Protein Kinase Inhibitors
Pyrazoles
Pyridines
RNA, Messenger
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases

Grants and funding